Longitudinal gompertzian analysis of non-hodgkin's lymphoma mortality in the US, 1979–1988: Demonstration of the environmental basis for rising overall mortality

1993 ◽  
Vol 67 (1-2) ◽  
pp. 65-78 ◽  
Author(s):  
Jack E. Riggs ◽  
Kun Chen
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Us ◽  
Overall Mortality

Review of Current Patterns of Treatment and Costs in Follicular Non-Hodgkin’s Lymphoma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4676-4676
Author(s):  
Talia S. Foster ◽  
Jeffrey D. Miller ◽  
Mark E. Boye ◽  
Mason W. Russell
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Hodgkin’S Lymphoma ◽  
Cost Effective ◽  
Treatment Patterns ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Us ◽  
Economic Studies

Abstract Introduction Follicular non-Hodgkin’s lymphoma (FNHL) comprises about 15–30% of all incident NHL in developed countries. US SEER data show that the annual incidence rate per 100,000 persons is 3.0 and 1.3 (white and black males, respectively) and 2.7 and 0.9 (white and black females, respectively). Patients with this slow-growing malignancy may live for 10 years or more, but it is considered incurable with standard treatment. The common disease pattern is a series of relapses and remissions, with each relapse responding less to treatment, and each remission shorter than the preceding one. Little is known about patterns and costs of current treatment for FNHL. Methods. We conducted a systematic review of the English-language, MEDLINE-indexed literature on FNHL published during the 10-year period beginning in May 1997 and ending in May 2007. The following search algorithm was used, with keywords in the title or abstract: (nodular OR follicular) AND non-Hodgkin‘s AND lymphoma[ti] NOT PCR NOT „case reports“[pt]. Government and organization-sponsored websites also were searched using these keywords. No geographic restrictions were used. Results: Literature identified. We manually reviewed the initial search results of 375 articles to identify those relevant to this research on FNHL treatment patterns and costs. Authors of 16 primary research studies reported treatment patterns (5) and/or costs (15). The 5 studies of treatment patterns were conducted in the UK (2), Canada (1), the Netherlands (1), and the US (1); the 15 economic studies were conducted in the US (5), UK (3), Canada (2), Spain (2), France (1), Germany (1), and the Netherlands (1). Nine of the 16 studies were published as abstracts from professional meetings (1 reporting treatment, all 9 reporting costs). Results: Treatment patterns. Studies reporting primary data on FNHL treatment patterns tended to assess these data during the 1990s, prior to the adoption of rituximab + chemotherapy as the current standard of treatment. No more than 13 patients received rituximab in each of these studies. Of the 5 studies of treatment patterns we identified, 1 collected data through 1998, 2 through 2001, and 1 did not collect drug-specific data. One UK study reported treatment patterns through August 2003, by which date 6 patients had received rituximab. Results: Costs. The 15 cost studies identified comprised 3 cost analyses using databases (2 US, 1 UK), 2 primary studies of costs (1 US, 1 Netherlands), and 1 primary study assessing work impact (Canada). There were also 8 economic models, including 6 cost-effectiveness analyses (1 with two publications), 1 budgetary impact model, and 1 model calculating total treatment costs. Most of these 15 economic studies focus on rituximab and fludarabine. Findings suggest that the high initial cost of rituximab is offset by its low incidence of adverse events, producing equivalent average annual direct costs to those of fludarabine. Maintenance with rituximab is cost-effective versus observation alone, and the addition of rituximab to systemic chemotherapy is cost-effective versus chemotherapy alone. The single study of indirect costs (work loss) indicates highest costs among patients receiving systemic therapy. Available economic data in FNHL do not include broader societal impact of the disease. Conclusions. Although the introduction of biological therapies such as rituximab has shifted the treatment paradigm for FNHL, few studies published in the last 10 years have evaluated treatment patterns and costs of this disease. As new treatments enter the market, primary cost data and other economic information about FNHL will be needed to evaluate their relative cost-effectiveness.

Improving Relative Survival, But Large Remaining Differences in Survival for Non-Hodgkin's Lymphoma Across Europe and the United States From 1990 to 2004

2011 ◽  
Vol 29 (2) ◽  
pp. 192-199 ◽  
Author(s):  
Saskia A.M. van de Schans ◽  
Adam Gondos ◽  
Dick Johan van Spronsen ◽  
Jadwiga Rachtan ◽  
Bernd Holleczek ◽  
...  
Keyword(s):  
United States ◽  
Hodgkin’S Lymphoma ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Hodgkin's Lymphoma ◽  
Term Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
The Us

PurposeNon-Hodgkin's lymphoma (NHL) is the most common hematologic malignant neoplasm in adults. Monitoring differential changes in population-based survival is across Europe and the United States (US) could point to progress attained and impact of application of novel treatments.Patients and MethodsWe examined trends in age-specific 5-year relative survival among patients with NHL age 15 years or older between 1990 and 1994 and 2000 and 2004, on the basis of follow-up data from 12 population-based cancer registries across Europe, using period analysis techniques and compared the results with similar trends of patients with NHL in the US, as recorded in the Surveillance, Epidemiology, and End Results database.ResultsBy 2000 to 2004, overall 5-year relative survival of patients with NHL across Europe was between 37% and 62%, achieved by overall increases in 5-year relative survival ranging from 4% to 12% units between 1990 and 1994 and 2000 and 2004. Changes in age-specific survival ranged from −1% to 43% units during the same time interval. For patients with NHL older than age 55 years, relative survival in individual European registries for the whole period was between 8% and 36% units lower than in the US, theoretically representing a lag of 4 to 10 years of progress.ConclusionOur analyses disclosed a strong and ongoing increase in long-term survival for patients with NHL in European populations. The geographic differences potentially indicate that further improvements could be possible, especially for patients age 55 years or older. The presumptive delay in improvement in survival among elderly patients with NHL in Europe remains to be clarified.

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Sign in / Sign up

Export Citation Format

Share Document